Viking Therapeutics, Inc. (NASDAQ: VKTX)

$30.84 ▼ -0.88 (-2.77%)

As of May 12, 2026 12:11 PM

Sector: Healthcare Industry: Biotechnology CIK: 0001607678

Market Cap 3.51 Bn

P/E -9.78

Div. Yield 0.00

Add ratio to table...

About

Viking Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of novel first in class or best in class therapies for metabolic and endocrine disorders. The company advances a pipeline of drug candidates that target obesity non alcoholic steatohepatitis X linked adrenoleukodystrophy and other related conditions. Its most advanced program is VK2735 a dual agonist of the glucagon like peptide 1 and glucose dependent insulinotropic polypeptide receptors being developed in both subcutaneous and oral formulations. Additional...

Viking Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of novel first in class or best in class therapies for metabolic and endocrine disorders. The company advances a pipeline of drug candidates that target obesity non alcoholic steatohepatitis X linked adrenoleukodystrophy and other related conditions. Its most advanced program is VK2735 a dual agonist of the glucagon like peptide 1 and glucose dependent insulinotropic polypeptide receptors being developed in both subcutaneous and oral formulations. Additional programs include VK2809 a selective thyroid hormone receptor beta agonist for liver disease VK0214 for a rare neurological disorder VK5211 for muscle preservation after hip fracture and a preclinical dual amylin and calcitonin receptor agonist platform.

As a clinical stage entity Viking Therapeutics Inc does not yet generate revenue from product sales. The company's current income stems from collaboration agreements licensing arrangements and research funding. It has entered into manufacturing agreements that secure future capacity but do not produce immediate revenue. The firm anticipates future revenue from the commercialization of its pipeline candidates should they receive regulatory approval and reach the market.

In the obesity therapeutics market Viking Therapeutics Inc competes with established players such as Novo Nordisk which markets Wegovy and Saxenda and Eli Lilly which offers Zepbound. The company's VK2735 candidate aims to differentiate itself through dual receptor agonism and the availability of both subcutaneous and oral dosing options. In the NASH space Viking's VK2809 faces competition from Madrigal Pharmaceuticals' Resmetirom and various early stage programs from companies including Gilead and Pfizer. VK2809's clinical data show a favorable safety profile and potent effects on liver fat and fibrosis which the company views as a competitive edge. For rare diseases like X linked adrenoleukodystrophy there are currently no approved therapies giving VK0214 a potential first mover advantage if it succeeds clinically. Overall Viking Therapeutics leverages its proprietary molecule platforms and disciplined clinical development to carve out a niche within competitive therapeutic areas.

The company's ultimate customers will be patients suffering from obesity non alcoholic steatohepatitis X linked adrenoleukodystrophy and related conditions as well as the health care providers who prescribe these therapies. While specific partner names are not disclosed in the filing Viking Therapeutics intends to collaborate with pharmaceutical companies for licensing and co development opportunities. Its manufacturing agreements with Corden Pharma indicate a reliance on contract manufacturers for future commercial supply.

Investment thesis

Bull case

Viking Therapeutics has secured a pivotal manufacturing partnership with CordenPharma that spans both active pharmaceutical ingredient production and fill‑and‑finish services for its dual GLP‑1/GIP co‑agonist, VK2735, across subcutaneous and oral routes. The agreement is structured to be fully transferable, ensuring that once clinical milestones are achieved, the company can scale production to meet a multi‑billion dollar revenue target without significant supply constraints. By locking in a proven peptide manufacturer early, Viking mitigates a common bottleneck for peptide drugs and positions itself to accelerate commercialization timelines, a critical factor in the fast‑moving obesity market where first‑mover advantage is rapidly eroding. The strategic alignment with a global leader also boosts investor confidence in the company’s operational readiness, which is often a stumbling block for small biotechs.
The dual‑agonist mechanism of VK2735—simultaneous activation of GLP‑1 and GIP receptors—provides a scientific edge over many single‑receptor agents that dominate the obesity space. Early Phase II data demonstrate up to 14.7% weight loss with weekly subcutaneous dosing and 12.2% with daily oral dosing, both with favorable safety profiles dominated by mild to moderate GI events. The extended half‑life of the molecule allows for a broad dosing window, facilitating both weekly and monthly regimens, and the oral tablet offers a non‑invasive option that could capture a sizable share of patients who are hesitant to use injections. Such versatility is a rare commodity among obesity therapeutics and could lead to higher adherence and sustained outcomes, thereby improving long‑term cost‑effectiveness for payors.
Viking’s clinical pipeline is diversified beyond obesity; the company is advancing a novel amylin receptor agonist, a mechanism that has shown early promise in appetite regulation. The planned IND filing and anticipated Phase I data this year will broaden Viking’s therapeutic portfolio, allowing cross‑learning and potential synergistic combinations with VK2735. If the amylin program shows early efficacy, it could position Viking as a multi‑disease player in the metabolic space, thereby attracting additional capital and strategic partnerships. Furthermore, the ability to leverage the same molecule across multiple delivery formats could streamline regulatory and commercial efforts, a benefit that larger competitors often struggle to replicate.
The launch readiness of the auto‑injector, validated by a bioequivalent study that will be introduced to the Phase III VANQUISH program within the current quarter, addresses a critical user experience barrier. By transitioning from vial‑and‑syringe to a pre‑filled, single‑dose device, Viking reduces the burden on patients and caregivers, potentially improving real‑world adherence and satisfaction metrics. This device also simplifies clinic visits and training requirements, translating into lower operational costs for providers and insurers. The company’s ability to deploy this technology concurrently with the oral tablet amplifies its differentiation, giving it a unique “two‑in‑one” competitive proposition that few peers can match.
Viking’s cash position—$706 million at year‑end—provides a financial cushion that covers the anticipated Phase III expenditures, the oral Phase III program, and the next milestone of the maintenance study. This runway supports continued clinical development without immediate capital raises, reducing dilution risk for existing shareholders. By aligning the cash burn rate with expected clinical milestones, the company demonstrates prudent financial stewardship that aligns with the industry standard for late‑stage biotech ventures. The solid balance sheet also offers leverage in negotiations with payors and distributors, potentially facilitating early commercial agreements that lock in pricing and reimbursement.

Viking Therapeutics has secured a pivotal manufacturing partnership with CordenPharma that spans both active pharmaceutical ingredient production and fill‑and‑finish services for its dual GLP‑1/GIP co‑agonist, VK2735, across subcutaneous and oral routes. The agreement is structured to be fully transferable, ensuring that once clinical milestones are achieved, the company can scale production to meet a multi‑billion dollar revenue target without significant supply constraints. By locking in a proven peptide manufacturer early, Viking mitigates a common bottleneck for peptide drugs and positions itself to accelerate commercialization timelines, a critical factor in the fast‑moving obesity market where first‑mover advantage is rapidly eroding. The strategic alignment with a global leader also boosts investor confidence in the company’s operational readiness, which is often a stumbling block for small biotechs.
The dual‑agonist mechanism of VK2735—simultaneous activation of GLP‑1 and GIP receptors—provides a scientific edge over many single‑receptor agents that dominate the obesity space. Early Phase II data demonstrate up to 14.7% weight loss with weekly subcutaneous dosing and 12.2% with daily oral dosing, both with favorable safety profiles dominated by mild to moderate GI events. The extended half‑life of the molecule allows for a broad dosing window, facilitating both weekly and monthly regimens, and the oral tablet offers a non‑invasive option that could capture a sizable share of patients who are hesitant to use injections. Such versatility is a rare commodity among obesity therapeutics and could lead to higher adherence and sustained outcomes, thereby improving long‑term cost‑effectiveness for payors.
Viking’s clinical pipeline is diversified beyond obesity; the company is advancing a novel amylin receptor agonist, a mechanism that has shown early promise in appetite regulation. The planned IND filing and anticipated Phase I data this year will broaden Viking’s therapeutic portfolio, allowing cross‑learning and potential synergistic combinations with VK2735. If the amylin program shows early efficacy, it could position Viking as a multi‑disease player in the metabolic space, thereby attracting additional capital and strategic partnerships. Furthermore, the ability to leverage the same molecule across multiple delivery formats could streamline regulatory and commercial efforts, a benefit that larger competitors often struggle to replicate.
The launch readiness of the auto‑injector, validated by a bioequivalent study that will be introduced to the Phase III VANQUISH program within the current quarter, addresses a critical user experience barrier. By transitioning from vial‑and‑syringe to a pre‑filled, single‑dose device, Viking reduces the burden on patients and caregivers, potentially improving real‑world adherence and satisfaction metrics. This device also simplifies clinic visits and training requirements, translating into lower operational costs for providers and insurers. The company’s ability to deploy this technology concurrently with the oral tablet amplifies its differentiation, giving it a unique “two‑in‑one” competitive proposition that few peers can match.
Viking’s cash position—$706 million at year‑end—provides a financial cushion that covers the anticipated Phase III expenditures, the oral Phase III program, and the next milestone of the maintenance study. This runway supports continued clinical development without immediate capital raises, reducing dilution risk for existing shareholders. By aligning the cash burn rate with expected clinical milestones, the company demonstrates prudent financial stewardship that aligns with the industry standard for late‑stage biotech ventures. The solid balance sheet also offers leverage in negotiations with payors and distributors, potentially facilitating early commercial agreements that lock in pricing and reimbursement.

Bear case

The obesity therapeutic space is highly congested, with established players such as semaglutide (Wegovy) and tirzepatide (Mounjaro) already securing market share and brand recognition. VK2735, despite promising early data, must compete against a product with a proven track record, established reimbursement pathways, and a broader global launch footprint. The need to differentiate a dual‑agonist from these incumbents will require substantial marketing investment and a demonstrable superiority in efficacy or safety, both of which remain unproven in the Phase III setting. This crowded field raises the bar for market penetration and could compress the price premium that Viking would need to justify.
Regulatory approval for obesity therapeutics increasingly hinges on long‑term outcomes data, particularly for payor coverage. While Viking’s Phase III trials will provide robust efficacy and safety data, the design currently does not include a dedicated outcomes arm to demonstrate cardiovascular or metabolic benefits beyond weight loss. Without such data, payors may be reluctant to grant coverage, especially in markets where reimbursement for obesity drugs is already constrained. This could delay commercialization or force Viking to negotiate lower pricing, undermining the projected multi‑billion dollar revenue potential.
The company’s financial performance in 2025 reflected a net loss of $358.5 million, with research and development expenses tripling from the prior year. Even with $706 million in cash, the burn rate is projected at $60–$90 million per quarter, leaving a relatively narrow runway if Phase III outcomes are not favorable or if additional capital is required for marketing and distribution. The risk of dilution through future equity issuances, especially if the company cannot secure a high valuation at the next financing event, remains significant. This financial fragility could impact investor confidence and the ability to fund subsequent clinical milestones or commercialization activities.
The company’s oral formulation, while conceptually attractive, faces technical challenges that were not fully addressed in the transcript. Oral peptides are notoriously difficult to absorb, and the current tablet size and dose increments were deemed “high” in Phase II, suggesting potential issues with patient adherence or manufacturing scalability. Even with a bioequivalent auto‑injector study completed, the transition to an oral route may encounter unforeseen pharmacokinetic hurdles, such as variable bioavailability or dose‑limiting GI side effects, which could necessitate additional trials or reformulation. These uncertainties add a layer of risk to the projected timeline for an oral launch.
The management’s cautious disclosures in the Q&A section reveal a lack of transparency on several fronts. Key details such as exact dosing schedules for the maintenance study, specific adverse event rates beyond mild or moderate GI events, and the outcomes of the CordenPharma supply agreement remain vague. This opacity may indicate potential issues—such as manufacturing bottlenecks, regulatory setbacks, or safety signals—that the company is reluctant to disclose. Investors must therefore consider the possibility that hidden risks could emerge once the company progresses to later-stage trials or post‑marketing surveillance.

The obesity therapeutic space is highly congested, with established players such as semaglutide (Wegovy) and tirzepatide (Mounjaro) already securing market share and brand recognition. VK2735, despite promising early data, must compete against a product with a proven track record, established reimbursement pathways, and a broader global launch footprint. The need to differentiate a dual‑agonist from these incumbents will require substantial marketing investment and a demonstrable superiority in efficacy or safety, both of which remain unproven in the Phase III setting. This crowded field raises the bar for market penetration and could compress the price premium that Viking would need to justify.
Regulatory approval for obesity therapeutics increasingly hinges on long‑term outcomes data, particularly for payor coverage. While Viking’s Phase III trials will provide robust efficacy and safety data, the design currently does not include a dedicated outcomes arm to demonstrate cardiovascular or metabolic benefits beyond weight loss. Without such data, payors may be reluctant to grant coverage, especially in markets where reimbursement for obesity drugs is already constrained. This could delay commercialization or force Viking to negotiate lower pricing, undermining the projected multi‑billion dollar revenue potential.
The company’s financial performance in 2025 reflected a net loss of $358.5 million, with research and development expenses tripling from the prior year. Even with $706 million in cash, the burn rate is projected at $60–$90 million per quarter, leaving a relatively narrow runway if Phase III outcomes are not favorable or if additional capital is required for marketing and distribution. The risk of dilution through future equity issuances, especially if the company cannot secure a high valuation at the next financing event, remains significant. This financial fragility could impact investor confidence and the ability to fund subsequent clinical milestones or commercialization activities.
The company’s oral formulation, while conceptually attractive, faces technical challenges that were not fully addressed in the transcript. Oral peptides are notoriously difficult to absorb, and the current tablet size and dose increments were deemed “high” in Phase II, suggesting potential issues with patient adherence or manufacturing scalability. Even with a bioequivalent auto‑injector study completed, the transition to an oral route may encounter unforeseen pharmacokinetic hurdles, such as variable bioavailability or dose‑limiting GI side effects, which could necessitate additional trials or reformulation. These uncertainties add a layer of risk to the projected timeline for an oral launch.
The management’s cautious disclosures in the Q&A section reveal a lack of transparency on several fronts. Key details such as exact dosing schedules for the maintenance study, specific adverse event rates beyond mild or moderate GI events, and the outcomes of the CordenPharma supply agreement remain vague. This opacity may indicate potential issues—such as manufacturing bottlenecks, regulatory setbacks, or safety signals—that the company is reluctant to disclose. Investors must therefore consider the possibility that hidden risks could emerge once the company progresses to later-stage trials or post‑marketing surveillance.

Breakdown of Revenue (2025)

Peer comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	109.62 Bn	27.71	9.13	-
2	REGN	Regeneron Pharmaceuticals, Inc.	73.93 Bn	16.38	5.15	1.99 Bn
3	ALNY	Alnylam Pharmaceuticals, Inc.	40.50 Bn	147.21	12.86	-
4	RVMD	Revolution Medicines, Inc.	27.39 Bn	-24.25	33,000.01	-
5	ZLAB	Zai Lab Ltd	23.74 Bn	-135.44	97.90	0.20 Bn
6	MESO	Mesoblast Ltd	23.66 Bn	-185.34	1,375.67	0.12 Bn
7	RPRX	Royalty Pharma plc	21.54 Bn	27.99	9.06	8.95 Bn
8	ROIV	Roivant Sciences Ltd.	19.92 Bn	-32.48	3,470.34	-

Research Tools